{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T03:23:23Z","timestamp":1769225003254,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The rebound effect after stopping treatment with denosumab may be associated with rapid loss of the gains in bone mineral density achieved with treatment, high levels of bone remodeling markers, the occurrence of vertebral fractures, and even hypercalcemia.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 64-year-old osteoporotic Caucasian woman suffered from a fracture of her second lumbar vertebra in 2004. From January 2005, she was treated with denosumab for 9 years, with good densitometry results for her hip and lumbar areas, and no fractures over the last 6 years of treatment. Ten months after the treatment with denosumab was stopped, a cascade of vertebral fractures, including some in unusual locations (third thoracic vertebra), and multiple rib fractures in a context of hypercalcemia, suggested possible malignancy. A complete evaluation, including systemic, biological, and biopsy analyses, ruled out this hypothesis. The hypercalcemia was associated with normal plasma phosphate and vitamin D concentrations, and a high parathyroid hormone level, with an abnormal fixation of the lower lobe of the thyroid on sesta-methoxy-isobutyl-isonitrile scintigraphy. Histological analysis of the excised parathyroid tissue revealed hyperplasia. The associated thyroidectomy (goiter) led to the discovery of a thyroid papillary microcarcinoma.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We consider the consequences of this rebound effect, not only in terms of the major loss of bone density (return to basal values within 3 years) and the multiple disabling fracture episodes, but also in terms of the hypercalcemia observed in association with apparently autonomous tertiary hyperparathyroidism. Several cases of spontaneous reversion have been reported in children, but the intervention in our patient precluded any assessment of the possible natural course. The discovery of an associated thyroid neoplasm appears to be fortuitous. Better understanding of the various presentations of the rebound effect after stopping treatment with denosumab would improve diagnostic management of misleading forms, as in this case. Bisphosphonates could partially prevent this rebound effect.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02401-0","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T18:04:46Z","timestamp":1597341886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Long-term follow up after denosumab treatment for osteoporosis \u2013 rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-8524","authenticated-orcid":false,"given":"Yves","family":"Maugars","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Gl\u00e9marec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Berthelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Le Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christelle","family":"Darrieutort-Laffite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"2401_CR1","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"3","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;3:1291\u20136.","journal-title":"J Bone Miner Res"},{"key":"2401_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jbspin.2019.07.010","volume":"87","author":"J Dupont","year":"2020","unstructured":"Dupont J, Laurent MR, Dedeyne L, Luyten FP, Gielen E, Dejaeger M. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases. Joint Bone Spine. 2020;87:171\u20133. https:\/\/doi.org\/10.1016\/j.jbspin.2019.07.010.","journal-title":"Joint Bone Spine"},{"key":"2401_CR3","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez Fern\u00e1ndez E, Benavent N\u00fa\u00f1ez D, Bonilla Hern\u00e1n G, Monjo Henry I, Garc\u00eda Carazo S, Bernad Pineda M, Balsa Criado A, Aguado AP. Multiple Vertebral Fractures Following Discontinuation of Denosumab Treatment: Ten Clinical Cases Report. Reumatol Clin. 2019; https:\/\/doi.org\/10.1016\/j.reuma.2018.11.002. [Epub ahead of print].","DOI":"10.1016\/j.reuma.2018.11.002"},{"issue":"2","key":"2401_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semarthrit.2019.02.007","volume":"49","author":"H Florez","year":"2019","unstructured":"Florez H, Ram\u00edrez J, Monegal A, Gua\u00f1abens N, Peris P. Spontaneous vertebral fractures after denosumab discontinuation: A case collection and review of the literature. Semin Arthritis Rheum. 2019;49(2):197\u2013203.","journal-title":"Semin Arthritis Rheum"},{"key":"2401_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K. Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int. 2018;103:50\u20134.","journal-title":"Calcif Tissue Int"},{"key":"2401_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00223-018-0389-1","volume":"103","author":"L Tripto-Shkolnik","year":"2018","unstructured":"Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I. Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int. 2018;103:44\u20139.","journal-title":"Calcif Tissue Int"},{"key":"2401_CR7","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","volume":"27","author":"AS Koldkj\u00e6r S\u00f8lling","year":"2016","unstructured":"Koldkj\u00e6r S\u00f8lling AS, Harsl\u00f8f T, Kaal A, Rejnmark L, Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int. 2016;27:2383\u20136.","journal-title":"Osteoporos Int"},{"key":"2401_CR8","doi-asserted-by":"publisher","unstructured":"Kurucu N, Akyuz C, Ergen FB, et al. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases. Pediatr Blood Cancer. 2018;65(4) https:\/\/doi.org\/10.1002\/pbc.26926. Epub 2017 Dec 29. PubMed PMID: 29286564.","DOI":"10.1002\/pbc.26926"},{"key":"2401_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1210\/jc.2017-02025","volume":"103","author":"S Uday","year":"2018","unstructured":"Uday S, Gaston CL, Rogers L, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018;103:596\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"2401_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","volume":"34","author":"N Setsu","year":"2016","unstructured":"Setsu N, Kobayashi E, Asano N, et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2016;34:118\u201322.","journal-title":"J Bone Miner Metab"},{"key":"2401_CR11","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pbc.25393","volume":"62","author":"N Gossai","year":"2015","unstructured":"Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62:1078\u201380.","journal-title":"Pediatr Blood Cancer"},{"key":"2401_CR12","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"AM Boyce","year":"2012","unstructured":"Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res. 2012;27:1462\u201370.","journal-title":"J Bone Miner Res"},{"key":"2401_CR13","first-page":"76","volume":"18","author":"P Trejo","year":"2018","unstructured":"Trejo P, Rauch F, Ward L. Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2018;18:76\u201380.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2401_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bone.2018.12.012","volume":"120","author":"S Roux","year":"2019","unstructured":"Roux S, Massicotte MH, Huot Daneault A, Brazeau-Lamontagne L, Dufresne J. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. Bone. 2019;120:482\u20136.","journal-title":"Bone."},{"key":"2401_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1574886313666180608080355","volume":"13","author":"EE Mazokopakis","year":"2018","unstructured":"Mazokopakis EE. Denosumab-induced normocalcemic hyperparathyroidism in in a woman with postmenopausal osteoporosis and normal renal function. Curr Drug Saf. 2018;13:214\u20136. https:\/\/doi.org\/10.2174\/1574886313666180608080355.","journal-title":"Curr Drug Saf"},{"key":"2401_CR16","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00223-017-0357-1","volume":"102","author":"Y Maugars","year":"2018","unstructured":"Maugars Y, Bart G, Guillot P, et al. Multiple vertebral osteonecroses (K\u00fcmmell's Disease) after 10 years on denosumab: is osteocyte apoptosis to blame? Calcif Tissue Int. 2018;102:368\u201372.","journal-title":"Calcif Tissue Int"},{"key":"2401_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000447372","volume":"39","author":"F Chen","year":"2016","unstructured":"Chen F, Pu F. Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials. Oncol Res Treat. 2016;39:453\u20139.","journal-title":"Oncol Res Treat"},{"key":"2401_CR18","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26:2773\u201383.","journal-title":"Osteoporos Int"},{"key":"2401_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12902-015-0077-3","volume":"15","author":"Y Nakamura","year":"2015","unstructured":"Nakamura Y, Kamimura M, Ikegami S, et al. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study. BMC Endocr Disord. 2015;15:81\u20136.","journal-title":"BMC Endocr Disord"},{"key":"2401_CR20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1681\/ASN.V132551","volume":"13","author":"A Torres","year":"2002","unstructured":"Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13:551\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2401_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","volume":"179","author":"E Gonzalez-Rodriguez","year":"2020","unstructured":"Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O. Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat. 2020;179:153\u20139. https:\/\/doi.org\/10.1007\/s10549-019-05458-8.","journal-title":"Breast Cancer Res Treat"},{"key":"2401_CR22","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.mayocpiqo.2019.02.003","volume":"3","author":"A Tyan","year":"2019","unstructured":"Tyan A, Patel SP, Block S, Hughes T, McCowen KC. Rebound Vertebral Fractures in a Patient with Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale. Mayo Clin Proc Innov Qual Outcomes. 2019;3:235\u20137.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2401_CR23","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bone.2019.03.019","volume":"123","author":"A Fassio","year":"2019","unstructured":"Fassio A, Adami G, Benini C, Vantaggiato E, Saag KG, Giollo A, Lippolis I, Viapiana O, Idolazzi L, Orsolini G, Rossini M, Gatti D. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone. 2019;123:191\u20135.","journal-title":"Bone."},{"key":"2401_CR24","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229\u201338.","journal-title":"J Bone Miner Res"},{"key":"2401_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","volume":"62","author":"AF de Groot","year":"2018","unstructured":"de Groot AF, Appelman-Dijkstra NM, van der Burg SH, Kroep JR. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review. Cancer Treat Rev. 2018;62:18\u201328.","journal-title":"Cancer Treat Rev"},{"key":"2401_CR26","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1177\/000313481708301224","volume":"83","author":"NA Sahbaz","year":"2017","unstructured":"Sahbaz NA, Tutal F, Aksakal N, et al. Cancer frequency in retrosternal goiter. Am Surg. 2017;83:1390\u20133.","journal-title":"Am Surg"},{"key":"2401_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr Osteoporos Rep. 2019;17:8\u201315.","journal-title":"Curr Osteoporos Rep"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02401-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02401-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T23:18:10Z","timestamp":1628637490000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02401-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2401"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02401-0","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Inclusion in the FREEDOM protocol signed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We do not have any competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}